ES2533266T3 - Purificación de anticuerpos mediante cromatografía de intercambio catiónico - Google Patents
Purificación de anticuerpos mediante cromatografía de intercambio catiónico Download PDFInfo
- Publication number
- ES2533266T3 ES2533266T3 ES08844379.1T ES08844379T ES2533266T3 ES 2533266 T3 ES2533266 T3 ES 2533266T3 ES 08844379 T ES08844379 T ES 08844379T ES 2533266 T3 ES2533266 T3 ES 2533266T3
- Authority
- ES
- Spain
- Prior art keywords
- cation exchange
- nacl
- month
- purification
- exchange chromatography
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Abstract
Un método para purificar un anticuerpo de una composición que comprende el anticuerpo y al menos un contaminante, comprendiendo dicho método las etapas secuenciales de: (a) cargar la composición en un material de intercambio catiónico en donde la composición está a un primer pH de 4,0 a 6,0; (b) lavar el material de intercambio catiónico con un primer tampón de lavado, en donde el pH del primer tampón de lavado es de 6,8 a 9,0; (c) lavar el material de intercambio catiónico con un segundo tampón de lavado de un pH de 5,0 a 6,0; y (d) eluir el anticuerpo del material de intercambio catiónico con un tampón de elución a una conductividad que es al menos 2 mS/cm mayor que la del segundo tampón de lavado.
Description
E08844379
18-03-2015
Este ejemplo describe un proceso mejorado de cromatografía de intercambio catiónico para purificar un anticuerpo contra CD20, rituximab. Rituximab se usa para terapia de NHL, CLL, RA, MS, etc. La estructura de la molécula de 5 Rituximab se describe en el documento 5.736.137, Anderson et al., así como en las Fig. 1A-1B de este documento. Rituximab está disponible en el mercado en Genentech, Inc.
Se usa cromatografía de intercambio catiónico para reducir adicionalmente los niveles de CHOP, ADN, proteína A lixiviada, garamicina (GENTAMYCIN®), agregados de Rituximab, y virus potenciales. Rituximab se une a la columna
10 en las condiciones de carga. La columna después se lava, eluye, regenera/desinfecta, y almacena hasta el siguiente uso. Pueden usarse múltiples ciclos para procesar un lote completo de combinación de afinidad. La combinación de intercambio catiónico puede mantenerse a temperatura ambiente hasta 30 ºC durante hasta 3 días o a 5 ºC durante hasta 7 días.
15 La resina de intercambio catiónico (POROS 50 HS®, Applied Biosystems) se compacta en una columna hasta una altura de lecho de 17-33 cm. Antes de cargar la combinación de afinidad, se purga la columna de intercambio catiónico de solución de almacenamiento con tampón de equilibrado. Después del equilibrado, la combinación de afinidad se carga en la columna. El producto se une a la columna en estas condiciones. La columna después se lava con tampón de lavado 1, seguido de tampón de lavado 2. Rituximab se eluye de la columna usando un tampón de
20 elución de alta fuerza iónica.
Se proporciona una comparación de las condiciones para el proceso de la presente invención en comparación con el proceso original (control) en la siguiente tabla.
25 Tabla 1: Comparación de tampones para procesos de cromatografía de intercambio catiónico de Rituximab
- Fase
- Composición de tampón (proceso original) Composición de tampón (proceso ejemplificado)
- Pre-equilibrado
- MES 20 mM, NaCl 500 mM, pH 5,50 Ninguna
- Equilibrado
- MES 20 mM, NaCl 60 mM, pH 5,50 MES 19 mM, NaCl 60 mM, pH 5,50
- Carga
- Combinación de proteína A condicionada, pH 5,00, densidad de carga ≤ 50 g/l de resina Combinación de proteína A condicionada, pH 5,00, densidad de carga ≤ 50 g/l de resina
- Lavado 1
- MES 20 mM, NaCl 60 mM, pH 5,50 HEPES 25 mM, pH 7,80
- Lavado 2
- Ninguno MES 19 mM, NaCl 10 mM, pH 5,50
- Elución
- MES 20 mM, NaCl 160 mM, MES 19 mM, NaCl 160 mM,
- pH 5,50
- pH 5,50
- Regeneración
- MES 20 mM, NaCl 500 mM, pH 5,50 Ninguna
- Desinfección
- NaOH 0,5 N NaOH 0,5 N
- Almacenamiento
- NaOH 0,1 N NaOH 0,1 N
Los intervalos deseados de pH, conductividad y molaridad para la carga y los tampones en el proceso de rituximab se proporcionan en la siguiente tabla.
Tabla 2: Intervalos preferidos de pH, conductividad y molaridad para el proceso de Rituximab
- Tampón
- Composición de tampón pH diana Intervalo preferido de molaridad de tampón Intervalo preferido de pH de tampón Intervalo permitido de conductividad para tampones
- Equilibrado
- MES 19 mM, NaCl 60 mM 5,5 MES 14 -23mM NaCl 50 -70 mM 5,0 -6,0 5,0 -7,2 mS/cm
- Carga
- Combinación de Proteína A condicionada 5,0 NA 4,5 -5,5 2,5 -5,5 mS/cm
- Lavado 1
- HEPES 25 mM 7,8 HEPES 15 -35 mM 7,5 -8,1 0,5 -1,5 mS/cm
- Lavado 2
- MES 19 mM NaCl 10 mM 5,5 MES 14 -23mM NaCl 5 -15 mM 5,0 -6,0 0,6 -2,2 mS/cm
- Elución
- MES 19 mM NaCl 160 mM 5,5 MES 14 -23 mM NaCl 140 -180 mM 5,3 -5,7 13,4 -17,2 mS/cm
- Desinfección
- NaOH 0,5 N NA NA NA NA
- Almacenamiento
- NaOH 0,1 N NA NA NA NA
- * Valores de conductividad medidos con compensación de temperatura basándose en una temperatura de 20 ºC y un valor alfa de 1,77.
El proceso ejemplificado para purificación de Rituximab potenció la robustez de la eliminación de proteínas de la célula hospedadora posibilitando una mayor retirada de proteínas de la célula hospedadora en las fases de lavado, provocando niveles inferiores de proteínas de la célula hospedadora en la combinación de producto (combinación de 35 elución) y facilitando la retirada de las impurezas en la posterior etapa corriente abajo. La Fig. 3 ilustra las ventajas
17
Claims (1)
-
imagen1 imagen2
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98382507P | 2007-10-30 | 2007-10-30 | |
US983825P | 2007-10-30 | ||
PCT/US2008/081516 WO2009058812A1 (en) | 2007-10-30 | 2008-10-29 | Antibody purification by cation exchange chromatography |
Publications (2)
Publication Number | Publication Date |
---|---|
ES2533266T3 true ES2533266T3 (es) | 2015-04-08 |
ES2533266T5 ES2533266T5 (es) | 2018-04-18 |
Family
ID=40262967
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES12189190.7T Active ES2572958T3 (es) | 2007-10-30 | 2008-10-29 | Purificación de anticuerpos mediante cromatografía de intercambio catiónico |
ES14189095.4T Active ES2666170T3 (es) | 2007-10-30 | 2008-10-29 | Purificación de anticuerpos mediante cromatografía de intercambio catiónico |
ES08844379.1T Active ES2533266T5 (es) | 2007-10-30 | 2008-10-29 | Purificación de anticuerpos mediante cromatografía de intercambio catiónico |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES12189190.7T Active ES2572958T3 (es) | 2007-10-30 | 2008-10-29 | Purificación de anticuerpos mediante cromatografía de intercambio catiónico |
ES14189095.4T Active ES2666170T3 (es) | 2007-10-30 | 2008-10-29 | Purificación de anticuerpos mediante cromatografía de intercambio catiónico |
Country Status (32)
Country | Link |
---|---|
US (3) | US20090148435A1 (es) |
EP (4) | EP3441402A1 (es) |
JP (5) | JP5237382B2 (es) |
KR (3) | KR20140015166A (es) |
CN (3) | CN103554215B (es) |
AR (2) | AR069097A1 (es) |
AU (1) | AU2008318865B2 (es) |
BR (1) | BRPI0817182A2 (es) |
CA (1) | CA2703279C (es) |
CL (1) | CL2008003218A1 (es) |
CO (1) | CO6280422A2 (es) |
CY (1) | CY1116129T1 (es) |
DK (3) | DK2840090T3 (es) |
ES (3) | ES2572958T3 (es) |
HK (4) | HK1182401A1 (es) |
HR (2) | HRP20150282T4 (es) |
HU (3) | HUE027668T2 (es) |
IL (4) | IL205310A0 (es) |
ME (1) | ME02101B (es) |
MX (1) | MX2010004740A (es) |
NZ (1) | NZ584839A (es) |
PE (1) | PE20091434A1 (es) |
PH (1) | PH12013501128A1 (es) |
PL (3) | PL2215117T5 (es) |
PT (1) | PT2215117E (es) |
RS (1) | RS53850B2 (es) |
RU (1) | RU2498991C2 (es) |
SG (2) | SG10201401690XA (es) |
SI (3) | SI2565206T1 (es) |
TW (2) | TWI448330B (es) |
WO (1) | WO2009058812A1 (es) |
ZA (2) | ZA201002850B (es) |
Families Citing this family (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA036531B1 (ru) * | 2003-11-05 | 2020-11-19 | Роше Гликарт Аг | Гуманизированное антитело типа ii к cd20 (варианты), фармацевтическая композиция, содержащая эти варианты антитела, и их применение |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
EP3698807A1 (en) * | 2005-01-21 | 2020-08-26 | Genentech, Inc. | Fixed dosing of her antibodies |
AU2006216732C1 (en) | 2005-02-23 | 2017-07-20 | Genentech, Inc. | Extending time to disease progression or survival in cancer patients using a HER dimerization inhibitor |
US8911964B2 (en) | 2006-09-13 | 2014-12-16 | Abbvie Inc. | Fed-batch method of making human anti-TNF-alpha antibody |
AU2007294731B2 (en) | 2006-09-13 | 2014-04-17 | Abbvie Inc. | Cell culture improvements |
WO2008109440A2 (en) | 2007-03-02 | 2008-09-12 | Genentech, Inc. | Predicting response to a her dimerisation inhibitor based on low her3 expression |
RS53850B2 (sr) * | 2007-10-30 | 2018-07-31 | Genentech Inc | Pročišćavanje antitela hromatografijom izmene katjona |
TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至her2結構域ii之抗體及其酸性變異體的組合物 |
BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
TW201014605A (en) | 2008-09-16 | 2010-04-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
JP5856845B2 (ja) | 2008-10-20 | 2016-02-10 | アッヴィ・インコーポレイテッド | 抗体精製中におけるウイルスの不活性化 |
CA2932207A1 (en) | 2008-10-20 | 2010-12-09 | Abbvie Inc. | Isolation and purification of antibodies using protein a affinity chromatography |
AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
WO2011037983A1 (en) | 2009-09-23 | 2011-03-31 | Medarex, Inc. | Cation exchange chromatography |
AR080794A1 (es) * | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
SI2552961T1 (en) * | 2010-03-30 | 2018-02-28 | Janssen Biotech, Inc. | Humanized antibodies against IL-25 |
HUE037227T2 (hu) | 2010-05-14 | 2018-08-28 | Univ Oregon Health & Science | Rekombináns HCMV és RHCMV vektorok és alkalmazásuk |
ES2637613T5 (es) * | 2010-05-25 | 2022-07-20 | Hoffmann La Roche | Procedimientos de purificación de polipéptidos |
GB201012603D0 (en) | 2010-07-27 | 2010-09-08 | Ucb Pharma Sa | Protein purification |
WO2012084829A1 (en) * | 2010-12-21 | 2012-06-28 | F. Hoffmann-La Roche Ag | Isoform enriched antibody preparation and method for obtaining it |
EP2691411B1 (en) * | 2011-03-29 | 2020-02-26 | GlaxoSmithKline LLC | Buffer system for protein purification |
US20140107321A1 (en) * | 2011-05-26 | 2014-04-17 | Dr. Reddy's Laboratories Limited | Purification of antibodies |
SI2691530T1 (en) | 2011-06-10 | 2018-08-31 | Oregon Health & Science University | CMV glycoproteins and recombinant vectors |
WO2013054250A1 (en) * | 2011-10-10 | 2013-04-18 | Dr Reddy's Laboratories Limited | Purification method |
DK2766040T3 (da) | 2011-10-14 | 2019-07-22 | Hoffmann La Roche | Pertuzumab, trastuzumab, docetaxel og carboplatin til behandling af brystkræft i et tidligt stadie |
RU2478646C1 (ru) * | 2011-11-28 | 2013-04-10 | Федеральное государственное бюджетное учреждение науки Институт молекулярной биологии им.В.А.Энгельгардта Российской академии наук (ИМБ РАН) | Способ получения высокоаффинных поликлональных антител |
TR201815709T4 (tr) | 2011-12-22 | 2018-11-21 | Hoffmann La Roche | İyon değişim membranı kromatografisi. |
HUE056217T2 (hu) | 2012-07-13 | 2022-02-28 | Roche Glycart Ag | Bispecifikus anti-VEGF/anti-ANG-2 antitestek és ezek alkalmazása szemészeti érbetegségek kezelésében |
WO2014034644A1 (ja) * | 2012-08-27 | 2014-03-06 | 旭化成メディカル株式会社 | 温度応答性クロマトグラフィーによる抗体の精製方法 |
CN103217499B (zh) * | 2013-01-15 | 2015-12-02 | 珠海市丽珠单抗生物技术有限公司 | 一种测定免疫球蛋白电荷异构体的糖基化和末端修饰情况的方法 |
WO2014137903A2 (en) * | 2013-03-08 | 2014-09-12 | Genzyme Corporation | Integrated continuous manufacturing of therapeutic protein drug substances |
UY35517A (es) | 2013-04-04 | 2014-10-31 | Mabxience S A | Un procedimiento para aumentar la formación de ácido piroglutamico de una proteína |
AR095863A1 (es) | 2013-04-16 | 2015-11-18 | Genentech Inc | Variantes de pertuzumab, su evaluación, método de tratamiento, método de preparación y artículo de fabricación |
KR101700580B1 (ko) | 2013-10-30 | 2017-02-13 | (주)셀트리온 | 양이온 교환 크로마토그래피를 이용한 항체의 아형 분리 방법 |
CN104628846B (zh) * | 2013-11-06 | 2019-12-06 | 三生国健药业(上海)股份有限公司 | 重组蛋白质的纯化方法 |
WO2015077605A1 (en) | 2013-11-25 | 2015-05-28 | Seattle Genetics, Inc. | Preparing antibodies from cho cell cultures for conjugation |
TWI709569B (zh) | 2014-01-17 | 2020-11-11 | 美商健臻公司 | 無菌層析樹脂及其用於製造方法的用途 |
TWI671312B (zh) | 2014-01-17 | 2019-09-11 | 美商健臻公司 | 無菌層析法及製法 |
EP3102589A1 (en) * | 2014-02-04 | 2016-12-14 | Biogen MA Inc. | Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications |
CN106103465B (zh) | 2014-03-10 | 2021-01-08 | 吉瑞工厂 | 使用预清洗步骤的免疫球蛋白纯化 |
CN105017418B (zh) * | 2014-03-27 | 2021-02-23 | 上海药明康德新药开发有限公司 | 单克隆抗体纯化工艺方法 |
EP3134440A1 (en) | 2014-04-25 | 2017-03-01 | F. Hoffmann-La Roche AG | Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab |
UA120938C2 (uk) | 2014-07-16 | 2020-03-10 | Орегон Хелс Енд Сайєнс Юніверсіті | Цитомегаловірус людини, що містить екзогенний антиген |
CN105315369B (zh) * | 2014-07-25 | 2020-03-13 | 山东博安生物技术有限公司 | 利用阳离子交换层析纯化蛋白质 |
AU2016233557B2 (en) * | 2015-03-13 | 2021-06-24 | Bristol-Myers Squibb Company | Use of alkaline washes during chromatography to remove impurities |
EP3302551A2 (en) | 2015-05-30 | 2018-04-11 | H. Hoffnabb-La Roche Ag | Methods of treating her2-positive locally advanced or previously untreated metastatic breast cancer |
KR101657690B1 (ko) * | 2015-06-05 | 2016-09-19 | 주식회사 녹십자홀딩스 | 혈장 유래 b형 간염 사람 면역글로불린 제제의 제조방법 |
WO2017087280A1 (en) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
US10688164B2 (en) | 2015-11-20 | 2020-06-23 | Oregon Health & Science University | CMV vectors comprising microRNA recognition elements |
GB201600512D0 (en) | 2016-01-12 | 2016-02-24 | Univ York | Recombinant protein production |
US11197937B2 (en) | 2016-04-15 | 2021-12-14 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
EP3454903A4 (en) * | 2016-05-13 | 2020-08-19 | Askgene Pharma, Inc. | NEW ANGIOPOIETIN-2, VEGF DUAL ANTAGONISTS |
CN109415427A (zh) * | 2016-07-15 | 2019-03-01 | 豪夫迈·罗氏有限公司 | 用于纯化聚乙二醇化的***的方法 |
CN106222222B (zh) * | 2016-08-08 | 2019-10-29 | 湖北医药学院 | 一种重组人白血病抑制因子的制备方法 |
WO2018045587A1 (zh) * | 2016-09-12 | 2018-03-15 | 广东东阳光药业有限公司 | 一种抗vegf类单克隆抗体的纯化方法 |
CN106380519B (zh) * | 2016-10-17 | 2019-11-01 | 深圳万乐药业有限公司 | 一种单克隆抗体的纯化方法 |
AU2017346788A1 (en) | 2016-10-18 | 2019-05-02 | Oregon Health & Science University | Cytomegalovirus vectors eliciting T cells restricted by major histocompatibility complex E molecules |
US11021530B2 (en) * | 2016-10-31 | 2021-06-01 | Hexal Ag | Antibody preparation |
CN110099926A (zh) | 2016-12-28 | 2019-08-06 | 豪夫迈·罗氏有限公司 | 晚期her2表达性癌症的治疗 |
RU2750821C2 (ru) | 2017-01-17 | 2021-07-05 | Дженентек, Инк. | Препараты антител против her2 для подкожного введения |
FI3589661T3 (fi) | 2017-03-02 | 2024-01-31 | Genentech Inc | Her2-positiivisen rintasyövän adjuvanttihoito |
BE1025090B1 (fr) | 2017-03-30 | 2018-10-29 | Univercells Sa | Procede et kit de purification de proteines |
TWI679209B (zh) * | 2017-04-14 | 2019-12-11 | 南韓商Cj醫藥健康股份有限公司 | 使用陽離子交換層析法純化同功抗體之方法 |
CN110536969A (zh) | 2017-04-24 | 2019-12-03 | 豪夫迈·罗氏有限公司 | 跨膜或近膜域中的erbb2/her2突变 |
MX2019015304A (es) * | 2017-06-21 | 2020-02-17 | Cephalon Inc | Amortiguador de lavado para cromatografia de intercambio cationico. |
CN111163804A (zh) * | 2017-09-22 | 2020-05-15 | 伊缪诺金公司 | 使用阳离子交换色谱法分离三轻链抗体 |
CN110272491B (zh) * | 2018-03-13 | 2023-01-24 | 江苏恒瑞医药股份有限公司 | 一种抗pd-1抗体的纯化工艺 |
CN112313248A (zh) * | 2018-03-29 | 2021-02-02 | 百时美施贵宝公司 | 纯化单体单克隆抗体的方法 |
US11612885B2 (en) * | 2018-05-08 | 2023-03-28 | Waters Technologies Corporation | Methods, compositions and kits useful for pH gradient cation exchange chromatography |
WO2020046602A1 (en) | 2018-08-31 | 2020-03-05 | Genzyme Corporation | Sterile chromatography resin and use thereof in manufacturing processes |
EP3643322A1 (en) * | 2018-10-26 | 2020-04-29 | Mabion SA | Low aggregate anti cd20 ligand formulation |
CN109320611B (zh) * | 2018-10-31 | 2022-06-03 | 鼎康(武汉)生物医药有限公司 | 一种人鼠嵌合单克隆抗体生物类似药的纯化方法 |
CN112206327A (zh) * | 2019-07-12 | 2021-01-12 | 上海药明生物技术有限公司 | 一种抗体偶联药物的制备及其高通量筛选方法 |
EP4045917A1 (en) * | 2019-10-14 | 2022-08-24 | Pierce Biotechnology, Inc. | Peptide purification formulations and methods |
BR112022010069A2 (pt) * | 2019-11-25 | 2022-09-06 | Akeso Biopharma Inc | Anticorpo biespecífico, molécula de ácido nucleico isolada, vetor, célula hospedeira, conjugado, kit, uso do anticorpo biespecífico e composição farmacêutica |
KR102153258B1 (ko) * | 2020-02-21 | 2020-09-07 | 프레스티지바이오로직스 주식회사 | 베바시주맙 정제의 최적화된 방법 |
US11416468B2 (en) * | 2020-07-21 | 2022-08-16 | International Business Machines Corporation | Active-active system index management |
CN114591438B (zh) * | 2022-04-25 | 2023-12-05 | 达石药业(广东)有限公司 | 一种采用阳离子交换层析法纯化双特异性抗体的方法 |
CN115850493B (zh) * | 2022-11-08 | 2024-03-12 | 江苏耀海生物制药有限公司 | 一种二价纳米抗体Cablivi的分离纯化方法 |
Family Cites Families (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
US4515893A (en) | 1979-04-26 | 1985-05-07 | Ortho Pharmaceutical Corporation | Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells |
GB2070818A (en) | 1980-02-04 | 1981-09-09 | Philips Electronic Associated | Regulated power supply for an image intensifier |
WO1984002129A1 (en) | 1982-11-22 | 1984-06-07 | Takeda Chemical Industries Ltd | Human immune interferon protein and process for its preparation |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US6054561A (en) | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
US4753894A (en) | 1984-02-08 | 1988-06-28 | Cetus Corporation | Monoclonal anti-human breast cancer antibodies |
US5169774A (en) | 1984-02-08 | 1992-12-08 | Cetus Oncology Corporation | Monoclonal anti-human breast cancer antibodies |
WO1986002068A1 (en) * | 1984-09-26 | 1986-04-10 | Takeda Chemical Industries, Ltd. | Mutual separation of proteins |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
US5196323A (en) | 1985-04-27 | 1993-03-23 | Boehringer Ingelheim International Gmbh | Process for preparing and purifying alpha-interferon |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US5525338A (en) * | 1992-08-21 | 1996-06-11 | Immunomedics, Inc. | Detection and therapy of lesions with biotin/avidin conjugates |
US5091178A (en) | 1986-02-21 | 1992-02-25 | Oncogen | Tumor therapy with biologically active anti-tumor antibodies |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
CA1283072C (en) | 1986-12-01 | 1991-04-16 | Timothy Durance | Process for the isolation and separation of lysozyme and avidin from eggwhite |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US5451662A (en) | 1987-10-23 | 1995-09-19 | Schering Corporation | Method of purifying protein |
US5118796A (en) * | 1987-12-09 | 1992-06-02 | Centocor, Incorporated | Efficient large-scale purification of immunoglobulins and derivatives |
US5091313A (en) | 1988-08-05 | 1992-02-25 | Tanox Biosystems, Inc. | Antigenic epitopes of IgE present on B cell but not basophil surface |
WO1989006692A1 (en) * | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
IT1219874B (it) | 1988-03-18 | 1990-05-24 | Fidia Farmaceutici | Utilizzazione del fattore di crescita nervoso umano e sue composizioni farmaceutiche |
US5115101A (en) | 1988-06-08 | 1992-05-19 | Miles Inc. | Removal of protein A from antibody preparations |
DE68919361T2 (de) | 1988-06-21 | 1995-05-24 | Genentech Inc | Therapeutische zusammensetzungen für die behandlung von myocard-infarkten. |
DE68925971T2 (de) | 1988-09-23 | 1996-09-05 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5112951A (en) | 1989-07-28 | 1992-05-12 | Hybritech Incorporated | Separation of anti-metal chelate antibodies |
US5110913A (en) * | 1990-05-25 | 1992-05-05 | Miles Inc. | Antibody purification method |
EP0467466A1 (en) * | 1990-07-16 | 1992-01-22 | Eastman Kodak Company | Method for the purification of immunoreactive labeled thyroxine conjugates |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
ES2206447T3 (es) | 1991-06-14 | 2004-05-16 | Genentech, Inc. | Anticuerpo humanizado para heregulina. |
CA2113813C (en) | 1991-08-14 | 2005-04-12 | Paula M. Jardieu | Immunoglobulin variants for specific fc epsilon receptors |
US7018809B1 (en) | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
JPH07501451A (ja) | 1991-11-25 | 1995-02-16 | エンゾン・インコーポレイテッド | 多価抗原結合タンパク質 |
JPH05202098A (ja) | 1992-01-29 | 1993-08-10 | Snow Brand Milk Prod Co Ltd | 乳質原料から生理活性物質の製造法 |
AU675929B2 (en) | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
US5279823A (en) | 1992-06-08 | 1994-01-18 | Genentech, Inc. | Purified forms of DNASE |
MX9305070A (es) | 1992-08-21 | 1994-04-29 | Genentech Inc | Compocicion farmaceutica que contiene un antagonista de lfa-1 para el tratamiento de transtornos o desordenes mediados por el lfa-1 |
CA2149329C (en) | 1992-11-13 | 2008-07-15 | Darrell R. Anderson | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
WO1995016203A2 (en) | 1993-12-10 | 1995-06-15 | Genentech, Inc. | Methods for diagnosis of allergy and screening of anti-allergy therapeutics |
DK0739214T3 (da) | 1994-01-18 | 1998-10-07 | Genentech Inc | Fremgangsmåde til behandling af parasitinfektionerunder anvendelse af IgE antagonister |
US5429746A (en) | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
WO1995023865A1 (en) | 1994-03-03 | 1995-09-08 | Genentech, Inc. | Anti-il-8 monoclonal antibodies for treatment of inflammatory disorders |
US5534615A (en) | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5714583A (en) | 1995-06-07 | 1998-02-03 | Genetics Institute, Inc. | Factor IX purification methods |
CA2222231A1 (en) | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth of tumors |
US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
EP1297847A3 (en) | 1996-01-23 | 2003-05-07 | Genentech, Inc. | Anti-CD18 antibodies in stroke |
US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
AU729459B2 (en) | 1996-11-15 | 2001-02-01 | Genentech Inc. | Purification of neurotrophins |
EP1864999B1 (en) | 1996-11-27 | 2009-03-18 | Genentech, Inc. | Affinity purification of polypeptide on protein a matrix |
IL130143A0 (en) | 1996-11-27 | 2000-06-01 | Genentech Inc | Humanized anti-CD11a antibodies |
EP0973804B1 (en) | 1997-04-07 | 2006-12-27 | Genentech, Inc. | Anti-vegf antibodies |
US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
EP3260468A1 (en) | 1997-04-07 | 2017-12-27 | Genentech, Inc. | Anti-vegf antibodies |
PT1860187E (pt) | 1997-05-15 | 2011-10-04 | Genentech Inc | Receptor apo-2 |
US5994511A (en) | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
ATE321066T1 (de) | 1998-05-06 | 2006-04-15 | Genentech Inc | Anti-her2 antikörperzusammensetzung |
WO1999062936A1 (en) | 1998-06-01 | 1999-12-09 | Genentech, Inc. | Separation of protein monomers from aggregates by use of ion-exchange chromatography |
DK1084147T3 (da) | 1998-06-09 | 2004-10-25 | Statens Seruminstitut | Fremgangsmåde til fremstilling af immunglobuliner til administration og andre immunglobulinprodukter |
EP1189641B1 (en) | 1999-06-25 | 2009-07-29 | Genentech, Inc. | HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
IL149116A0 (en) | 1999-10-29 | 2002-11-10 | Genentech Inc | Anti-prostate stem cell antigen (psca) antibody compositions and methods of use |
UA83458C2 (uk) | 2000-09-18 | 2008-07-25 | Байоджен Айдек Ма Інк. | Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf) |
US6417355B1 (en) | 2001-04-11 | 2002-07-09 | The United States Of America As Represented By The Secretary Of The Navy | Geminal-dinitro-1-5 diazocine derivatives |
GB0113179D0 (en) * | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
US7321026B2 (en) | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
US6770027B2 (en) * | 2001-10-05 | 2004-08-03 | Scimed Life Systems, Inc. | Robotic endoscope with wireless interface |
AU2002351495A1 (en) | 2001-10-17 | 2003-04-28 | Human Genome Sciences, Inc. | Neutrokine-alpha and neutrokine-alpha splice variant |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
CA2476166C (en) | 2002-02-14 | 2011-11-15 | Immunomedics, Inc. | Anti-cd20 antibodies and fusion proteins thereof and methods of use |
CN1671741A (zh) * | 2002-06-21 | 2005-09-21 | 拜奥根Idec公司 | 浓缩抗体的缓冲剂制剂及其使用方法 |
ES2629602T5 (es) | 2002-09-11 | 2021-06-08 | Genentech Inc | Purificación de proteínas |
SI1558648T1 (sl) | 2002-10-17 | 2012-05-31 | Genmab As | Človeška monoklonalna protitelesa proti CD |
MXPA05006306A (es) | 2002-12-13 | 2005-09-21 | Mitra Medical Technology Ab | Agentes de direccionamiento antilinfoma con funciones efectoras y de afinidad enlazados a traves de un reactivo trifuncional. |
DE60332957D1 (de) | 2002-12-16 | 2010-07-22 | Genentech Inc | Immunoglobulinvarianten und deren verwendungen |
NZ571243A (en) | 2002-12-31 | 2010-04-30 | Altus Pharmaceuticals Inc | Complexes of protein crystals and ionic polymers comprising human growth hormone and protamine |
JPWO2004087761A1 (ja) * | 2003-03-31 | 2006-07-27 | 麒麟麦酒株式会社 | ヒトモノクローナル抗体およびヒトポリクローナル抗体の精製 |
WO2005000901A2 (en) | 2003-05-09 | 2005-01-06 | Duke University | Cd20-specific antibodies and methods of employing same |
AR044388A1 (es) | 2003-05-20 | 2005-09-07 | Applied Molecular Evolution | Moleculas de union a cd20 |
AU2004263538B2 (en) | 2003-08-08 | 2009-09-17 | Immunomedics, Inc. | Bispecific antibodies for inducing apoptosis of tumor and diseased cells |
US8147832B2 (en) | 2003-08-14 | 2012-04-03 | Merck Patent Gmbh | CD20-binding polypeptide compositions and methods |
KR100524074B1 (ko) | 2003-10-01 | 2005-10-26 | 삼성전자주식회사 | 베젤 구조를 가지는 전자기기 |
TW200533357A (en) * | 2004-01-08 | 2005-10-16 | Millennium Pharm Inc | 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases |
CN101022829A (zh) * | 2004-04-16 | 2007-08-22 | 健泰科生物技术公司 | 用抗cd20抗体治疗多软骨炎和多发性单神经炎 |
RU2006140374A (ru) * | 2004-04-16 | 2008-05-27 | Дженентек, Инк. (Us) | Лечение нарушений |
EP1833970A2 (en) * | 2004-12-22 | 2007-09-19 | Genentech, Inc. | Methods for producing soluble multi-membrane-spanning proteins |
MX2007011129A (es) * | 2005-03-11 | 2007-11-06 | Wyeth Corp | Un metodo de cromatografia de particion debil. |
EA015148B1 (ru) * | 2005-06-17 | 2011-06-30 | Элан Фарма Интернэшнл Лимитед | СПОСОБЫ ОЧИСТКИ Aβ-СВЯЗЫВАЮЩЕГО БЕЛКА, СОДЕРЖАЩЕГО ОБЛАСТЬ FC |
WO2007028154A2 (en) * | 2005-09-02 | 2007-03-08 | Northwestern University | Encapsulated arsenic drugs |
WO2007108955A1 (en) * | 2006-03-20 | 2007-09-27 | Medarex, Inc. | Protein purification |
NZ611859A (en) † | 2006-04-05 | 2014-12-24 | Abbvie Biotechnology Ltd | Antibody purification |
US8513393B2 (en) * | 2006-08-28 | 2013-08-20 | Ares Trading S.A. | Process for the purification of Fc-containing proteins |
US8620738B2 (en) | 2006-08-31 | 2013-12-31 | Visa U.S.A. Inc | Loyalty program incentive determination |
JP5456658B2 (ja) * | 2007-03-30 | 2014-04-02 | メディミューン,エルエルシー | 抗体製剤 |
RS53850B2 (sr) * | 2007-10-30 | 2018-07-31 | Genentech Inc | Pročišćavanje antitela hromatografijom izmene katjona |
JP5731726B1 (ja) | 2014-06-26 | 2015-06-10 | 楽天株式会社 | 情報処理装置、情報処理方法及び情報処理プログラム |
-
2008
- 2008-10-29 RS RS20150156A patent/RS53850B2/sr unknown
- 2008-10-29 US US12/260,623 patent/US20090148435A1/en not_active Abandoned
- 2008-10-29 PL PL08844379T patent/PL2215117T5/pl unknown
- 2008-10-29 JP JP2010532193A patent/JP5237382B2/ja active Active
- 2008-10-29 AU AU2008318865A patent/AU2008318865B2/en active Active
- 2008-10-29 TW TW097141614A patent/TWI448330B/zh active
- 2008-10-29 NZ NZ584839A patent/NZ584839A/en unknown
- 2008-10-29 TW TW103117553A patent/TWI554517B/zh active
- 2008-10-29 PT PT88443791T patent/PT2215117E/pt unknown
- 2008-10-29 ES ES12189190.7T patent/ES2572958T3/es active Active
- 2008-10-29 ES ES14189095.4T patent/ES2666170T3/es active Active
- 2008-10-29 EP EP18151178.3A patent/EP3441402A1/en not_active Withdrawn
- 2008-10-29 DK DK14189095.4T patent/DK2840090T3/en active
- 2008-10-29 RU RU2010121816/10A patent/RU2498991C2/ru active
- 2008-10-29 PL PL12189190T patent/PL2565206T3/pl unknown
- 2008-10-29 PE PE2008001848A patent/PE20091434A1/es active IP Right Grant
- 2008-10-29 WO PCT/US2008/081516 patent/WO2009058812A1/en active Application Filing
- 2008-10-29 HU HUE12189190A patent/HUE027668T2/en unknown
- 2008-10-29 CN CN201310495290.7A patent/CN103554215B/zh active Active
- 2008-10-29 HU HUE08844379A patent/HUE024877T2/en unknown
- 2008-10-29 ES ES08844379.1T patent/ES2533266T5/es active Active
- 2008-10-29 MX MX2010004740A patent/MX2010004740A/es active IP Right Grant
- 2008-10-29 EP EP08844379.1A patent/EP2215117B2/en active Active
- 2008-10-29 SI SI200831634A patent/SI2565206T1/sl unknown
- 2008-10-29 BR BRPI0817182 patent/BRPI0817182A2/pt not_active Application Discontinuation
- 2008-10-29 AR ARP080104725A patent/AR069097A1/es active IP Right Grant
- 2008-10-29 DK DK12189190.7T patent/DK2565206T3/en active
- 2008-10-29 SI SI200831945T patent/SI2840090T1/en unknown
- 2008-10-29 HU HUE14189095A patent/HUE037409T2/hu unknown
- 2008-10-29 CN CN200880119331XA patent/CN101889025B/zh active Active
- 2008-10-29 ME MEP-2015-34A patent/ME02101B/me unknown
- 2008-10-29 KR KR1020127028627A patent/KR20140015166A/ko not_active Application Discontinuation
- 2008-10-29 KR KR1020147036127A patent/KR20150008503A/ko not_active Application Discontinuation
- 2008-10-29 PL PL14189095T patent/PL2840090T3/pl unknown
- 2008-10-29 SI SI200831381T patent/SI2215117T2/en unknown
- 2008-10-29 CA CA2703279A patent/CA2703279C/en active Active
- 2008-10-29 SG SG10201401690XA patent/SG10201401690XA/en unknown
- 2008-10-29 EP EP14189095.4A patent/EP2840090B1/en active Active
- 2008-10-29 DK DK08844379.1T patent/DK2215117T4/en active
- 2008-10-29 KR KR1020107011765A patent/KR101241486B1/ko active IP Right Grant
- 2008-10-29 CN CN201510941252.9A patent/CN105315323A/zh active Pending
- 2008-10-29 CL CL2008003218A patent/CL2008003218A1/es unknown
- 2008-10-29 SG SG2011073087A patent/SG175597A1/en unknown
- 2008-10-29 EP EP12189190.7A patent/EP2565206B1/en active Active
-
2010
- 2010-04-22 ZA ZA2010/02850A patent/ZA201002850B/en unknown
- 2010-04-25 IL IL205310A patent/IL205310A0/en unknown
- 2010-05-21 CO CO10061141A patent/CO6280422A2/es active IP Right Grant
- 2010-10-28 HK HK13109765.9A patent/HK1182401A1/zh unknown
- 2010-10-28 HK HK10110121.9A patent/HK1143821A1/xx active IP Right Maintenance
-
2011
- 2011-03-23 ZA ZA2011/02169A patent/ZA201102169B/en unknown
-
2013
- 2013-03-21 JP JP2013059102A patent/JP2013173747A/ja not_active Withdrawn
- 2013-06-03 PH PH12013501128A patent/PH12013501128A1/en unknown
-
2014
- 2014-09-30 IL IL234902A patent/IL234902A0/en unknown
- 2014-09-30 IL IL234901A patent/IL234901A0/en unknown
- 2014-11-03 US US14/531,880 patent/US9896478B2/en active Active
-
2015
- 2015-02-19 JP JP2015030880A patent/JP5885864B2/ja active Active
- 2015-02-19 JP JP2015030881A patent/JP2015155406A/ja not_active Withdrawn
- 2015-03-12 HR HRP20150282TT patent/HRP20150282T4/hr unknown
- 2015-03-19 CY CY20151100275T patent/CY1116129T1/el unknown
- 2015-06-18 IL IL239495A patent/IL239495B/en not_active IP Right Cessation
- 2015-07-28 HK HK15107237.1A patent/HK1206753A1/xx unknown
-
2016
- 2016-07-12 JP JP2016137986A patent/JP2017019790A/ja active Pending
- 2016-08-08 HK HK16109407.0A patent/HK1221234A1/zh unknown
-
2017
- 2017-12-21 US US15/850,885 patent/US20180118781A1/en not_active Abandoned
-
2018
- 2018-03-09 AR ARP180100555A patent/AR111171A2/es unknown
- 2018-06-18 HR HRP20180943TT patent/HRP20180943T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2533266T3 (es) | Purificación de anticuerpos mediante cromatografía de intercambio catiónico | |
CN106103465B (zh) | 使用预清洗步骤的免疫球蛋白纯化 | |
JP7414874B2 (ja) | カプリル酸を用いてタンパク質を精製する方法 | |
Liu et al. | Exploration of overloaded cation exchange chromatography for monoclonal antibody purification | |
JP6463734B2 (ja) | 抗体を精製するための連続的多工程法 | |
DE602004006725T2 (de) | Reinigung von Antikörpern durch Protein A und Ionenaustauschromatographie | |
EP3004163B1 (en) | Method for purifying antibody | |
McCue | Theory and use of hydrophobic interaction chromatography in protein purification applications | |
HRP20200581T1 (hr) | Pojačano pročišćavanje proteina kroz eluiranje modificiranog proteina a | |
US20130178608A1 (en) | Protein purification by ion exchange | |
RU2016133483A (ru) | Способы стерильной хроматографии и производства | |
CN109336969B (zh) | 一种抗体的纯化方法 | |
US20210139535A1 (en) | Method for purifying antibodies | |
US20140128577A1 (en) | Purification of chimeric protein | |
Strauss et al. | Anion exchange chromatography provides a robust, predictable process to ensure viral safety of biotechnology products | |
CN106496302B (zh) | 一种用离子交换层析纯化蛋白质的方法 | |
Arunakumari et al. | Purification of Human Monoclonal Antibodies: Non‐Protein A Strategies | |
Ishihara et al. | Accelerated purification process development of monoclonal antibodies for shortening time to clinic: design and case study of chromatography processes | |
EP0261403A2 (de) | Polypeptide des Rhinovirusstammes HRV89 sowie die hierfür codierenden DNA-Moleküle | |
Lorenz et al. | The effect of low intensity ultraviolet‐C light on monoclonal antibodies | |
WO2013102822A1 (en) | Filtration method | |
Mahajan et al. | One resin, multiple products: A green approach to purification | |
Xu et al. | Disaggregation of high‐molecular weight species during downstream processing to recover functional monomer | |
EP1448297A1 (de) | VERFAHREN ZUR REDUKTION DES LIGANDEN- i leakage /i VON AFFINITÄTSCHROMATOGRAPHIE-MATRICES | |
Baur et al. | Intensified Production of Recombinant Proteins |